Training and upskilling are part of our genes

Talents — The world of life sciences is vast and constantly evolving. It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists. At Aixial Group, Stéphane Thérèse is well aware of this.

STÉPHANE THÉRÈSE /
DIVISION DIRECTOR — AIXIAL GROUP

What kind of profiles do we have today within the life sciences sector?

— We have a broad range of profiles within our life sciences division. Our teams include pharmacists, doctors, scientists, biologists, and the list goes on. This diversity is not just a strength, but the trademark of our unique market position.

How do you keep up with the training and career development of your talents while respecting this diversity of profiles?

— We have a 360° approach when it comes to training and development. We participate in many external conferences and promote knowledge sharing through communities, and together with the ALTEN Group, we are enhancing our training offerings. Career-wise, we also conduct transparent talent reviews and maintain a detailed profile mapping to accelerate our consultants’ growth.

Do you see new roles emerging? How can we envision the life sciences market within the next years?

— Life sciences is an ever-evolving industry. We are in the first stages of the next technological advancements, especially in AI. Due to the healthcare industry becoming more and more global, we can expect many new opportunities and developments for our people abroad within the next years. Studies tell us that 85% of the jobs in 2030 do not exist yet. However, we know that the new landscape will be 100% linked to AI and technology. I believe that we already have the qualified experts and that they will need to grow and adapt to keep pace with the upcoming changes.

How do ALTEN and Aixial Group anticipate these changes to keep on responding to clients’ needs?

— Our DNA is not simply knowing how to react to changes; but rather to anticipate and shape them. By making strategic investments and maintaining close relationships with our clients, we ensure that we can meet their expectations. Externally, we partner with top-tier universities, developing scientific programs. These initiatives allow us to identify young talents and play a role in shaping their careers, as it is paramount to stay connected to the next generation of talents.

TO GO FURTHER

Atomising cancer

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer.

A Phase II Open -Label Safety and Efficacy Study of combination IP in patients with progressed advanced malignancies

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.

Safety, Preliminary Efficacy and Pharmacokinetics of [IP] in Metastatic Castrate Resistant Prostate Cancer

Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases. The 5-year survival rate is close to 100%, largely thanks to advances in treatment and early detection.

Training and upskilling are part of our genes

Talents — The world of life sciences is vast and constantly evolving. It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists. At Aixial Group, Stéphane Thérèse is well aware of this.

Breast Cancer and Aixial Group’s Expertise

In recognition of Breast Cancer Awareness Month, Ashley Hunter, Head of Strategic Development and Delivery, offers valuable insights on the importance of early detection, the latest advancements and ongoing challenges in breast cancer research, and how Aixial Group is actively supporting the fight against breast cancer.